Boston Scientific (BSX) has recently been dropped from several Russell growth benchmarks, a broad index reshuffle that can affect how index funds hold the stock and may change short term trading volumes.

Over the past year Boston Scientific has shifted from strong multi year gains to clear selling pressure, with the share price at $44.99 and a 90 day share price return down 27.19% and a 1 year total shareholder return down 56.68%. Recent index removals and the completion of a Class II recall may be contributing to weaker momentum.

If this kind of sector specific volatility has you thinking about diversification in healthcare, it could be worth scanning opportunities in companies harnessing medical AI through the 40 healthcare AI stocks

For Boston Scientific, this sharp slide after years of gains raises a simple tension: are investors reacting to a real shift in the business, or has sentiment swung harder than the fundamentals justify, and what does that mean for valuation next?

Most Popular Narrative: 54.5% Undervalued

On the most followed narrative for Boston Scientific, a fair value of $98.90 sits well above the recent $44.99 close, which puts the current share price under a strong valuation spotlight.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:
* Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we''ve seen in the recent price dips.
* Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company''s leverage, with projections hitting 3.3x adjusted EBITDA leverage by the end of 2026.

Curious how a deal that initially weighs on earnings and lifts leverage can still support such a high fair value for Boston Scientific? The narrative leans on a specific mix of growth expectations, margin profile and timing of post acquisition earnings contribution that is anything but generic.

Result: Fair Value of $98.90 (UNDERVALUED)

However, Boston Scientific’s narrative could be challenged if the Penumbra integration disappoints or if higher debt and recall related scrutiny weigh more heavily than expected.

Next Steps

If the mixed signals around Boston Scientific leave you unsure, take a closer look at the details and review the situation while sentiment is still settling, starting with the 4 key rewards.

Looking for more investment ideas beyond Boston Scientific?

If Boston Scientific has you thinking more broadly about your portfolio, take a few minutes now to uncover other stocks that might deserve a closer look.

• Target potential value opportunities by checking companies that screen well on quality and pricing through the 44 high quality undervalued stocks.
• Prioritise resilience and sleep better at night by reviewing companies that pass the 73 resilient stocks with low risk scores.
• Hunt for future standouts before the crowd by scanning the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.